Fast Market Research announces the availability of the new Business Monitor International report, "Brazil Pharmaceuticals & Healthcare Report Q1 2016", on their comprehensive research portal

Boston, MA -- (SBWire) -- 12/16/2015 --Brazil's pharmaceutical market will become increasingly unattractive to pharmaceutical companies due to the growing fiscal tightening in the country. Multinational drugmakers will face the risk of revenue decreases, due to increasing generic competition and more intensified cost-containment measurement s.

Headline Expenditure Projections

Pharmaceuticals: BRL62.0bn (USD26.4bn) in 2014 to BRL65.8bn (USD19.8bn) in 2015; +6.1% in local currency terms and -25.0% in US dollar terms. Forecast in has been revised down from Q 4 15 .
Healthcare: BRL511.7bn (USD217.4bn) in 2014 to BRL558.7bn (USD167.7bn) in 2015; +9.2% in local currency terms and -22.8% in US dollar terms . Forecast in local currency has been revised upward from Q 4 15 .

Get More Details on this Report and a Full Table of Contents at Brazil Pharmaceuticals & Healthcare Report Q1 2016

Risk/Reward Index

Brazil scores 57.5 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fifth-most attractive pharmaceutical market in the Americas this quarter. We highlight that Brazil will continue to be the most important market for multinationals in Latin America. Its position has been very well reflected in this quarter's RRI scores, primarily a result of the country's consistent economic growth and the government's commitment to promoting local industry.

The Brazil Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Brazil Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Brazil pharmaceutical and healthcare industry.

Key Benefits

-Benchmark BMI's pharmaceutical and healthcare market forecasts for Brazil, to test other views - a key input for successful budgeting and strategic business planning in the Brazilian pharmaceutical and healthcare market.
-Target business opportunities and risks in the Brazilian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Brazil.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

BMI?s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market?s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape



About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
-Kenya Pharmaceuticals & Healthcare Report Q1 2016
-Ukraine Pharmaceuticals & Healthcare Report Q1 2016
-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Oman Pharmaceuticals & Healthcare Report Q1 2016